Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Aerovate Therapeutics, Inc. is a biopharmaceutical company focused on developing inhaled therapies for pulmonary arterial hypertension (PAH), a rare and serious lung disease. Its primary product candidate was AV-101, a dry powder inhaled formulation of imatinib designed to target abnormal cellular proliferation in pulmonary arteries. The company’s business model centers on drug development, clinical trials, and regulatory approval processes targeting PAH patients in the U.S. and Europe.
This description was generated via AI from an annual report. Updated about 1 year ago.